Parthenon Therapeutics

Parthenon Therapeutics is located in Cambridge, United States on 1 Broadway. Parthenon Therapeutics is rated 3 out of 5 in the category biotechnology in United States. Parthenon is focused on beating tough cancers. We operate at the intersection of tumor biology, pharmacology, and machine learning bringing together the most innovative science to advance a pipeline of first-in-class targeted therapeutics. The platform and pipeline is powered by a world-class scientific advisory board (MIT, Yale, Vanderbilt) and seasoned Pharma/biotech execs. We are also focused on helping out patient organizations using our approach. Despite leaps in biomedical, far too many cancers remain incurable and highly aggressive (Overall Survival < 50% @ 5 years). There is a high unmet medical need for transformative treatments. This requires understanding cancer as a complex disease, and matching treatment to patient tumor biology. Our co-founder (Vito Quaranta) is a world-class expert in cancer biology and heads one of a handful of nation-wide NIH consortiums focused on recalcitrant cancers (https://www.eurekalert.org/pub_releases/2018-06/vu-mg060818.php). He regularly publishes in Nature, Science, PNAS and co-authors with the world best scientific teams. In addition to this role, he leads Vanderbilt’s quantitative cancer systems biology center bringing together under one roof, biology, math, statistics, pharmacology, to develop novel approaches for tackling highly aggressive and incurable tumors. At the operational level, we’ve attracted a team of seasoned pharma/biotech execs and a world-class SAB (Yale, MIT, Vanderbilt). Our focus is to identify in a systematic and unbiased way novel therapeutic points to reprogram cancer cells, develop novel drugs, and take those novel medicines into the right patient population as soon as possible. We are leveraging cutting-edge science underpinned by a suite of technological tools encompassing single cell net-omics, ML-based algorithms, biological assays in the lab and patient selection tools to deconvolute complex diseases. Our pipeline consists of novel targets against different recalcitrant diseases.